Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

 (currently amended) A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,

wherein

R1 is hydrogen,

R2 is hydrogen or C1-20-alkyl,

R³ is hydrogen, C₁₋₂₀-alkyl, C₄₋₈-cycloalkyl, C₅₋₈-cycloalkylenyl, aryl, aromatic or non aromatic heterocycle, C₁₋₂₀-alkoxy, or a group of formula -W-R⁸.

R^{3a} is hydrogen, or C₁₋₂₀-alkyl, or a group of formula:

or NR3R3a is a group of formula

R4 is hydrogen,

 R^5 is hydrogen; nitro; halogen; azido; cyano; -S-C₁₋₄-alkyl; -SO-C₁₋₄-alkyl; -SO-C₁₋₄-alkyl; -SONH₂; C₁₋₂₀-alkyl unsubstituted or substituted by halogen; or C₁₋₂₀-alkoxy unsubstituted or substituted by halogen,

R6 is hydrogen, C1-20-alkyl or halogen,

 \boldsymbol{R}^{7} is hydrogen, $\boldsymbol{C}_{1\text{--}20}\text{--alkyl}$ or halogen,

W is C1-12-alkylene, -NH- or -NHC(=O)-,

(312)913-0001

X is O. S or NH.

Y is O, S, CR12R13, NR14 or C(=O)

R8 is aryl or heterocycle,

R⁰, R¹⁴, R¹⁴⁰ and R¹¹ are independently selected from hydrogen, C₁₋₁ alkyl, halogen, hydroxy or methoxycarbonyl.

or R¹⁰ and R^{10a} together form a C₃₋₆-alkylene,

R12 is hydrogen, C1-4-alkyl, halogen or hydroxy,

R13 is hydrogen,

or CR12R13-is dioxolanyl.

R14 is aryl, heterocycle or a group of formula -V-R15,

V is C1-12-alkylene,

R15 is aryl or heterocycle,

m is 1 to 4.

n is 0 or 1, and at least one of R^3 , R^6 and R^7 is different from hydrogen when R^2 is hydrogen, R^3 is H or 2, 6-diisopropylphenyl, and R^{3a} is H.

(currently amended) A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,

$$H_{\delta} = H_{\delta} + H_{\delta$$

wherein

R1 is hydrogen,

R2 is hydrogen or C1-4-alkyl,

R³ is hydrogen; C₁₋₆-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or-and alkylamino; C₅₋₇-cycloalkyl; (hydroxymethyl) cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C₁₋₄-alkyl, hydroxy, methoxy, nitro, methylsulfonyl, and trifluoromethylthio; or pyridinylalkyl; pyridinyl unsubstituted or

3

substituted by methoxy; triazolyl; C₁₋₄-alkoxy; or a group offormula-W-R⁸, R^{3a} is hydrogen. C₁₋₆-alkyl or a group of formula

or NR³R^{3a} is piperidinyl unsubstituted or substituted by hydroxy; thiomorpholinyl; thiazolidinyl unsubstituted or substituted byC₁₋₄-alkoxycarbonyl; 2,5-dihydro-1Hpyrrol-1-yl; 1,4-dioxa-8-azaspiro [4.5] dee-8-yl; 4-oxooctahydro-1 (2H) quinolinyl; or a group of formula

R4 is hydrogen.

R⁵ is hydrogen; nitro; halogen; C₁₋₄-alkyl, unsubstituted or substituted by halogen; or C₁₋₄-alkoxy unsubstituted or substituted by halogen,

R6 is hydrogen, C1-6-alkyl or halogen,

R7 is hydrogen, methyl or halogen,

W is C₁₋₄-alkylene unsubstituted or substituted by halogen, hydroxy, C₁₋₄-alkyl or alkoxy; -NH-; or -NHC (=0)-,

R⁸ is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C₁₋₄-allyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluoromethylthio; furyl unsubstituted or substituted by methyl; pyrazolyl; pyridinyl; morpholinyl; tetrahydrobenzazocinyl; piperidinyl unsubstituted or substituted by methyl; dihydroisochromenyl or dihydroimidazolyl;

R¹⁴-is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, C₁₋₄-alkyl; or a group of formula -V-R¹⁶;

V is unsubstituted C₁₋₄-alkylene,

R¹⁵ is phenyl or morpholinyl,

m is 1 to 4.

and at least one of R⁵, R⁶ and R⁷ is different from hydrogen when R² is hydrogen, R³ is H or 2,6-diisopropylphenyl, and R^{3a} is H.

 (currently amended) A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof.

$$R^{6}$$
 R^{6}
 R^{6}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{7}
 R^{8}
 R^{8}
 R^{8}
 R^{8}

wherein

R1 is hydrogen,

R2 is hydrogen, methyl or ethyl,

R³ is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-2,2-dimethylpropyl, 1-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3-ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dimethylamino)propyl, 6-(hydroxymethyl)cyclohex-3-en-1-yl, 3-hydroxyphenyl, 3-fluorophenyl,3-(2-pyridin-2-ylethyl) phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3-methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl,2-chloro-6-fluorobenzyl, 2-[(trifluoromethyl) thio] benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, [4-bromophenyl)amino, pyridin 3-yl, 6-methoxypyridin 3-yl, 4H-1,2,4-triazol-3-yl, pyridin 4-ylmethyl, [5-methyl-2-furyl)methyl, 3-(HI-pyrazol-1-yl)propyl, 2-morpholin 4-ylethyl, 2-((3,4,5,6-tetrahydro-1-benzazoein-1(2H)-yl)propyl, 2-(2-methylpiperidin-1-yl)ethyl, 3,4-dihydro-1H-imidazol-2-ylamino,

R3a is hydrogen, methyl or tetrahydrofuran 2-ylmethyl,

or NR³N^{3a} is 4R-pyridin 2-ylpiperazin 1-yl, 4-(3-methylphenyl)piperazin 1-yl, 4-(4-hydroxyphenyl)piperazin 1-yl, 4-(2-phenylethyl)piperazin 1-yl, 4-(2-morpholin-1-ylethyl)piperazin 1-yl, 3-hydroxypiperidin 1-yl, thiomorpholin 4-yl, 4.-methoxycarbonyl 1,3-thiazolidin 3-yl, 2,5-dihydro-1H-pyrrol-1-yl, 1.4-dioxa-8-azaspiro[4.5]dec-8-yl or 4-oxooctahydro-1(2H)-quinolinyl,

5

R4 is hydrogen,

- R⁵ is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl, isopropyl, nitro or halogen,
- R⁶ is hydrogen, methyl or Cl,
- R⁷ is hydrogen, methyl, Br, F or C1,
- and at least one of R⁵, R⁶ or R⁷ is different from hydrogen when R² is hydrogen, R³ is H
 or 2.6-diisopropylphenyl and R^{3a} is H.
- (previously presented) A compound according to claim 1 wherein R² is hydrogen or methyl.
- 5. (previously presented) A compound according to claim 1 wherein R³ is hydrogen.
- 6. (previously presented) A compound according to claim 1 wherein R^{3a} is hydrogen.
- (previously presented) A compound according to claim 1 wherein R⁵ is halogen or trifluoromethyl.
- 8. (previously presented) A compound according to claim 1 wherein R⁶ is hydrogen.
- (previously presented) A compound according to claim 1 wherein R⁷ is hydrogen, Br, or F.
- (previously presented) A compound according to claim 1 wherein R² is C₁₋₂₀-alkyl and the carbon atom to which R² is attached is in the "S"-configuration.
- 11. (currently amended) A compound selected from
 - 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
 - 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
 - 2-(5,7-dibromo-2-oxo-2,3-dihydro-1H-indol-1-y1)acetamide;
 - 2-(5-nitro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
 - 2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
 - 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;
 - (2R)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;
 - (2S)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;
 - 2-[2-oxo-5-(fluoromethoxy)-2,3-dihydro-1H-indo1-1-yl)acetamide;

- 2-(5-isopropyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(5-ethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-1-y1)acetamide;
- 2-(5.7-dimethyl-2-oxo-2.3-dihydro-1H-indol-1-yl)acetamide:
- 2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(2-oxo-5-propyl-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(2-oxo-5-(trifluoromethyl)-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(5.6-dimethyl-2-oxo-2.3-dihydro-1H-indol-1-yl)acetamide:
- 2-(7-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(6-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-yl)butanamide:
- (+)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide;
- (-)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)butanamide;
- 2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;
- (+)-2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-y1)propanamide;
- (-)-2-(5-methyl-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;
- 2-(5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide;
- (-)-2-(5-bromo-2-oxo-2,3-dihydr0-1H-indol-1-y1)propanamide;
- (+)-2-(5-bromo-2-oxo-2.3-dihydro-1H-indol-1-v1)propanamide:
- 2-(5-chloro-7-fluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxyphenyl)acetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-fluoroplenyl)acetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) N-[3-(2-pyridin-2-ylethyl)phonyl]acetamide;
- 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yllacetamide:
- 5 chloro 1 [2 oxo 2 (4 pyridin 2 y1piperzin 1 yl)ethyl] 1,3 dihydro 2H indol 2 one;
- 5-chloro 1- [2-[4-(3-methylphenyl)piperzin-1-yl] 2-oxoethyl] -1,3-dihydro 2H-indol 2-one;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-vl)-N-(4-hydroxy-3-

methoxybenzyl)acetamide;

- 2 (5 chloro 2 oxo 2,3 dihydro 1H indol 1 yl) N(pyridine 4 ylmethyl) N-(tetrahydrofuran 2 ylmethyl)acetamide:
- 5(chloro 1-[2-(3 hydroxypiperidin 1-yl) 2 oxoethyl] 1,3 dihydro 2H indol 2 one;
- 2 (5 chloro 2 oxo 2,3 dihydro 1H indol 1 vl) N' isonicotinovlacetohydrazide;
- 5-chloro-1 (2-oxo-2 thiomorpholin 4-ylethyl) 1,3-dihydro-2H indol-2-one;
- 2 (5 chloro 2 oxo 2.3 dihydro 1H indol 1 vl) N (4H 1.2.4 triazol 3 vl)acetamide:
- 2-(5-chloro2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[4-(methylsulfonyl)benzyl]acetamide;
- 1-[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]octahydroquinolin-4(1H)-one;
- N'- (4-bromophenyl)-2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-yl)acetohydrazide:
- 2 (5-chloro 2-oxo 2,3-dihydro-1H-indol-1-yl) N (6-methoxypyridin-3-yl) acetamide;
- N-butyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxypropyl)acetamide;
- 2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-yl)-N-[3-(dimethylamino)propyllacetamide:
- 5-chloro-1-(2-oxo-2-[4-(2-phenylethyl)piperazin-1-yl]ethyl}-l,3-dihydro-2H-indol-2-one:
- ethyl{[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]amino}acetate;
- 2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-vl)-N-(3-ethoxypropyl)acetamide:
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-fluoroethyl)acetamide;
- 2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-vl)-N-methoxy-N-methylacetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dimethylphenyl)acetamide;
- N-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxy-2,2-dimethylpropyl)acetamide;
- 2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-vl)-N-[1-(hydroxymethyl)propyllacetamide:
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide:
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-hydroxy-2-phenylethyl) acetamide;
- 5-chloro 1- (2 [4 (4 hydroxyphenyl) piperazin 1 yl] 2-oxoethyl} 1,3 dihydro 2H indol-2-one:
- 2 (5 chloro 2 oxo 2,3 dihydro 1H indol 1 vl) N (pyridin 4 ylmethyl)acetamide;

(312)913-0001

- 2 (5 chloro 2 oxo 2,3 dihydro 1H indol 1 yl) N [(5 methyl 2 furyl)methyl]acetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) N-[3-(1H-pyrazol-1-yl)propyl]acetamide;
- methyl 3 [(5 chloro 2 oxo 2,3 dihydro 1H indol 1 yl)acetyl] 1,3 thiazolidine 4 carboxylate:
- 5-chloro 1 [2-(2,5-dihydro-1H-pyrrol-1-yl) 2-oxoethyl] 1 3-dihydro-2H-indol-2-one;
- 2 (5 chloro 2 oxo 2,3 dihydro 1H indol 1 yl) N' (4,5 dihydro 1H imidazol 2yl)acetohydrazide:
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4-dimethoxyphenyl)ethyllacetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(2-chlorophenylethyl]acetamide;
- 2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-vl)-N-[2-(4-methylphenyl)ethyllacetamide:
- 2-(5-chloro-2-oxo-2.3-dihydro-1H-indol-1-yl) N-(2-morpholin-4-ylethyl)acetamide:
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4,5,6-tetrahydro-1-benzazocin-1(2H)-yl)propyl]acetamide;
- 2-(5-ehloro 2-oxo 2,3-dihydro-1H-indol-1-yl)-N-[2-(2-methylpiperidin-1-yl)ethyllacetamide:
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-nitrobenzyl)acetamide;
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dihydro-1H-isochromen-1-methyl)acetamide:
- N-(2-chloro-6-fluorobenzyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl) acetamide;
- N-benzyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methylacetamide:
- 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-{2-[(trifluoromethyl) thio] benzyl}acetamide:
- 5-chloro 1-[2-(1,4-dioxa-8-azaspiro[4.5]dee-8-yl) 2-oxoethyl] 1,3-dihydro-2H-indol-2-one;
- and 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-cycloheptylacetamide_;
- 5-chloro 1 [2 [4 (2 morpholin 4 ylethyl)piperazin 1 yl] 2 oxoethyl] 1,3 dihydro 2H-indol 2 one;
- and 2 (5-chloro 2 oxo 2,3-dihydro 1H-indol 1-yl) N-pyridin-3 ylacetamide.
- 12. (canceled)
- (canceled)

- 14. (canceled)
- 15. (currently amended) A compound having the formula VI or stereoisomeric forms thereof,

wherein

R1 is hydrogen,

R2 is hydrogen or C1-20-alkyl,

$$\begin{split} R^3 & is \ hydrogen, \ C_{1:20}\text{-}alkyl, \ C_{4:8}\text{-}cycloalkyl, \ C_{5:8}\text{-}cycloalkylenyl, \ \underline{or}\ aryl, \\ & \underline{aromatic\ heteroeyele}, \ C_{1:20}\text{-}alkoxy, \ or \ a \ group \ of \ formula\ -W-R^8, \end{split}$$

R3a is hydrogen; or C1-20-alkyl, or a group of formula:

or NR3R3e is a group of formula:

R4 is hydrogen.

R⁵ is hydrogen; halogen; azido; cyano; -S-C₁₋₄-alkyl; -SO-C₁₋₄-alkyl; -SO₂-C₁₋₄-alkyl; -SONH₂; or C₁₋₂₀-alkyl unsubstituted or substituted by halogen,

R6 is hydrogen, C1-20-alkyl or halogen,

R7 is hydrogen, C2-20-alkyl or halogen,

W is C₁₋₁₂-alkylene, -NH- or -NHC(=O)-,

X is O, S or NH,

Y is O, S, CR12R13, NR14 or C (=O)

```
R8 is arvl or beterocycle.
R<sup>9</sup>-R<sup>10</sup>-R<sup>10a</sup> and R<sup>11</sup> are independently selected from hydrogen, C<sub>1-4</sub>-alkyl, halogen,
    hydroxy or methoxycarbonyl.
or R10 and R10a together form a C14-alkylene.
R12 is hydrogen, C14 alkyl, halogen or hydroxy.
R<sup>+3</sup> is hydrogen, or CR<sup>+2</sup>R<sup>+3</sup> is dioxolanyl.
R14 is arvl, heterocycle or a group of formula-V-R15,
V isC_12-alkylene.
R15 is aryl or heterocycle-
m is 1 to 4.
n is 0 or 1.
and at least one of R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> is different from hydrogen when R<sup>2</sup> is hydrogen, R<sup>3</sup> is H
    or 2, 6-diisopropylphenyl, and R3a is H.
(canceled)
(currently amended) A compound which is selected from the group consisting of:
2 (5' methyl 2' oxospiro[1,3 dithiolane 2,3' indol1 1'(2'H) yl)acetamide:
2-[2'-oxo-5'-[(trifluoromethyl)oxylspiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-vllacetamide:
2-f5' (1-methylethyl) 2'-oxospiro[1,3-dithiolane-2,3'-indoll-1'(2'H)-yl]acetamide:
2-(5'-ethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;
2-(5'-fluoro-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-vI)acetamide:
2-(5'.7'-dimethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'acetamide:
2 (2' oxo 5' propylspiro[1,3 dithiolane 2,3' indol1 1'(2'H) yl)acetamide:
2-[2'-oxo-5' (trifluoromethyl)spiro[1,3-dithiolane 2,3' indol]-1'(2'H)-vl]acetamide;
2-(5',6'-dimethyl-2'-oxospiro[1,3-dithiolane 2,3'-indol]-1'(2'H)-yl)acetamide;
5'-methylspirol 1.3-dithiolane-2.3'-indol1-2'(1'H)-one:
5'-f(trifluoromethyl)oxylspirof1.3-dithiolane 2.3' indol1-2'(1'H)-one:
5' (1 methylethyl)spiro[1,3 dithiolane 2,3' indol] 2'(1'H) one;
5' ethylspiro[1,3 dithiolane 2,3' indol] 2'(1'H) one;
5'-fluorospiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
```

16.

17.

- 5',7'-dimethylspiro[1,3-dithiolane 2,3'-indol]-2'(1'H) one;
- 5'-propylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
- 5'-(trifluoromethyl)spiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;
- 5',6'-dimethylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H) one;
- 2-(5-chloro-1H-indol-1-yl)propanamide;
- 2-(7-chloro-1H-indol-1-yl)acetamide;
- 2-(6-chloro-1H-indol-1-yl)acetamide;
- 2-(5-chloro-1H-indol-1-yl)butanamide;
- 2-(5-methyl-1H-indol-1-yl)propanamide:
- 2-(5-bromo-1H-indol-1-vl)propanamide;
- 2-(7-fluoro-1H-indol-1-vl)acetamide;
- 2-(5-bromo-1H-indol-1-yl)acetamide;
- 2-(5-fluoro-1H-indol-1-yl)acetamide;
- 2-(5-chloro-1H-indol-1-yl)acetamide;
- (5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetic acid.
- (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier.

12

- 19. (canceled)
- 20. (canceled)
- 21. (canceled)